Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 4Triple Negative Breast Neoplasms 3Neuroectodermal Tumors, Primitive, Peripheral 2Leukemia, Myeloid, Acute 2Carcinoma, Renal Cell 2Wilms Tumor 1Squamous Cell Carcinoma of Head and Neck 1Sarcoma, Ewing 1Sarcoma 1Rhabdomyosarcoma 1Rhabdoid Tumor 1Recurrence 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Osteosarcoma 1Neuroblastoma 1Neoplasms 1Kidney Neoplasms 1Hepatoblastoma 1Endometrial Neoplasms 1Colorectal Neoplasms 1Central Nervous System Neoplasms 1Carcinoma, Ovarian Epithelial 1Carcinoma, Non-Small-Cell Lung 1Advanced Solid Tumor 1Advanced Ovarian Cancer 1

Interventions

pembrolizumab 6aldesleukin 6Cyclophosphamide 6fludarabine phosphate 5fludarabine 5Nivolumab 4durvalumab 3Sorafenib 3Radiotherapy 3Filgrastim 3Everolimus 3Axitinib 3Temozolomide 2Peripheral Blood Stem Cell Transplantation 2Isotretinoin 2Ipilimumab 2Interleukin-2 2Interferon-alpha 2Fluorouracil 2Dexamethasone 2Cyclosporine 2Bevacizumab 2vorolanib 1tremelimumab 1tocilizumab 1talazoparib 1spartalizumab 1sargramostim 1poly ICLC 1palbociclib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Kidney Neoplasms × talazoparib × Clear all
NCT04337970 2025-05-28

Talazoparib and Axitinib for People With Previously Treated Advanced Kidney Cancer

Memorial Sloan Kettering Cancer Center

Phase 1/2 Completed
23 enrolled
Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡